Microalbuminuria in diabetes mellitus

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 5, 2002, Pages 499-503

  Tobe, Sheldon W ^a   McFarlane, Philip Alan ^a   Naimark, David Malcolm ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIVITAMIN; NON PRESCRIPTION DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOLOGY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROTEIN URINE LEVEL; SCREENING; URINALYSIS;

EID: 0036376749     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. 1998 Clinical practice guidelines for the management of diabetes in Canada
2. Epidemiology of diabetes mellitus in Canada
3. Type 2 diabetes mellitus in Canada's First Nations: Status of an epidemic in progress
4. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus
5. The impact of cardiovascular disease on people with diabetes: The potential for prevention
6. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio
7. The clinical course of renal function in NIDDM patients with normo- and microalbuminuria
8. Screening and management of microalbuminuria in patients with diabetes mellitus. Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation
9. Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: A multicenter study
10. The DIAB-HYCAR Study
11. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs
12. Epidemiology of renal involvement in type II diabetics (NIDDM) in Catalonia
13. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: Design, organization, and patient recruitment
14. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy
15. The changing natural history of nephropathy in type I diabetes
16. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension
17. Is antihypertensive treatment the same for NIDDM and IDDM patients?
18. Glomerular permselectivity in early stages of overt diabetic nephropathy
19. Evolution of incipient nephropathy in type 2 diabetes mellitus
20. Progression of overt nephropathy in non-insulin-dependent diabetes
21. Urine albumin creatinine ratio and clinical correlates in a diabetic population
22. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: A seven-year prospective study
23. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia
24. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
25. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
26. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
27. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
28. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
29. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
30. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
31. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
32. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
33. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria
34. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study
35. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
36. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
37. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
38. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
39. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
40. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
41. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
42. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
43. Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
44. The 2000 Canadian recommendations for the management of hypertension: Part one - Therapy
45. Recommendations for the management and treatment of dyslipidema
46. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
47. Preserving renal function in adults with hypertension and diabetes: A consensus approach
48. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: A systematic review of the evidence